Search Results 1491-1500 of 13647 for monoclonal antibody
Serum monoclonal protein ≥ 1.0 g/dL; ≥ 200 mg of monoclonal protein in the ... Monoclonal plasmacytosis ≥ 30% (evaluable disease); Measurable ...
... monoclonal λ FLC, κ/λ >1.65 for patients with monoclonal κ FLC). Eastern Cooperative Oncology Group (ECOG) ≤ 2. Life expectancy ≥ 6 months. Adequate ...
Prior allogeneic stem cell transplantation or organ transplantation. 17. History of severe hypersensitivity reactions to other monoclonal antibodies or any
Treatment with biological agents (including monoclonal antibodies and ... History of ≥ Grade 3 infusion-related reaction associated with antibody administration, ...
... monoclonal antibodies < 28 days prior to randomization. Receipt of other investigational antiviral treatments (e.g., anti-BK monoclonal antibodies) within ...
Antibody-drug conjugates are targeted cancer therapies. They deliver potent drugs directly into cancer cells while minimizing harm to healthy tissue. These ...
At any time received any monoclonal antibody (including biosimilars) targeting TNFα, IL-12, or IL-23, or anti-integrin agents approved for CD (i.e. ...
Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular ...
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...
Patients must have myeloma that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chain (FLC).
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.